Icagen, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally-administered small molecule drugs that modulate ion channel targets. The company’s programs include ICA-17043, a Phase III clinical trial product, which is an inhibitor of the Gardos channel for the chronic prophylactic treatment of sickle cell disease; a lead compound under preclinical studies for epilepsy and neuropathic pain; a phase I clinical trial compound for atrial fibrillation; and compounds in preclinical studies for dementia, including Alzheimer’s disease. It also conducts drug discovery programs on therapeutics for pain disorders, inflammatory...